Illustration of the structures of designed bicyclic peptides conjugated with a vinyl sulfone warhead. The primary amino acid sequences of the designed peptides were followed by the inhibition rate at a fixed concentration of 10 μM or 1 μM. Those with potent inhibition of > 80% were further characterized for their IC50
 A series |  B series | ||
|---|---|---|---|
| Name | Amino acid sequences | Inhibition (%) | IC50 ± SD (nM) |
| BCP-1A | Ala-Cys-Val-Leu-Gln-Cys-Gly-Phe-Arg-Cys | 50.1% at 10 μM | - |
| BCP-1B | Ala-Cys-Val-Leu-Gln-Cys-Gly-Phe-Arg-Cys | 68.2% at 10 μM | - |
| BCP-2A | Ala-Cys-Ser-Gly-Phe-Arg-Cys-Arg-Val-Trp-Cys | 62.8% at 10 μM | - |
| BCP-2B | Ala-Cys-Ser-Gly-Phe-Arg-Cys-Arg-Val-Trp-Cys | 63.0% at 10 μM | - |
| BCP-3A | Ala-Cys-Ser-Gly-Phe-Arg-Pro-Cys-Arg-Val-Trp-Cys | 62.0% at 10 μM | - |
| BCP-3B | Ala-Cys-Ser-Gly-Phe-Arg-Pro-Cys-Arg-Val-Trp-Cys | 75.6% at 10 μM | - |
| BCP-4A | Ala-Cys-Ser-Gly-Phe-Arg-Cys-Arg-Pro-Val-Trp-Cys | 60.5% at 10 μM | - |
| BCP-4B | Ala-Cys-Ser-Gly-Phe-Arg-Cys-Arg-Pro-Val-Trp-Cys | 66.0% at 10 μM | - |
| BCP-5A | Ala-Cys-Arg-Gly-Ser-Gly-Cys-Pro-Asn-Ser-Thr-Cys | 53.4% at 10 μM | - |
| BCP-5B | Ala-Cys-Arg-Gly-Ser-Gly-Cys-Pro-Asn-Ser-Thr-Cys | 55.7% at 10 μM | - |
| BCP-6A | Ala-Cys-Gly-Ser-Gly-Arg-Cys-Ser-Gly-Val-Leu-Cys | 53.3% at 10 μM | - |
| BCP-6B | Ala-Cys-Gly-Ser-Gly-Arg-Cys-Ser-Gly-Val-Leu-Cys | 55.3% at 10 μM | - |
| BCP-7A | Ala-Cys-Ser-Gly-Thr-Arg-Cys-Ser-Gly-Phe-Leu-Cys | 50.1% at 10 μM | - |
| BCP-7B | Ala-Cys-Ser-Gly-Thr-Arg-Cys-Ser-Gly-Phe-Leu-Cys | 52.0% at 10 μM | - |
| BCP-8A | Ala-Cys-Ala-Gly-Arg-Cys-Pro-Ser-Ala- Cys-Leu | 82.2% at 1 μM | 357.43 ± 29.70 nM |
| BCP-8B | Ala-Cys-Ala-Gly-Arg-Cys-Pro-Ser-Ala- Cys-Leu | 96.8% at 1 μM | 153.63 ± 17.87 nM |
| BCP-8BNO | Ala-Cys-Ala-Gly-Arg-Cys-Pro-Ser-Ala- Cys-Leu | 8.7% at 1 μM | - |
-: no data. SD: standard deviation; TATA: 1,3,5-triacryloylhexahydro-1,3,5-triazine; TBMB: 1,3,5-tris(bromomethyl)benzene; BCP: bicyclic peptide; IC50: half-maximal inhibitory concentration